Comparative efficacy and safety of infliximab biosimilar (BCD-055) and innovator infliximab in patients with ankylosing spondylitis (results of international, multiple-center, double-blind phase I and phase III clinical studies)

This article presents results from two clinical trials of infliximab biosimilar, BCD-055, including comparative data on the pharmacokinetics (PK), efficacy and safety of BCD-055 and innovator infliximab (IFX) in patients with ankylosing spondylitis (AS).Objective: The purpose of phase I clinical stu...

Full description

Saved in:

Bibliographic Details
Main Authors:	D. E. Karateev, V. I. Mazurov, E. V. Zonova, O. B. Nesmeyanova, T. V. Plaksina, D. G. Krechikova, O. V. Reshetko, L. N. Denisov, I. G. Gordeev, T. G. Pokrovskaya, O. V. Antipova, T. V. Kropotina, T. V. Povarova, P. A. Shesternya, E. N. Ushakova, N. F. Soroka, A. M. Pristrom, A. V. Eremeeva, E. V. Chernyaeva, R. A. Ivanov, U. V. Usacheva
Format:	Article
Language:	Russian
Published:	IMA-PRESS LLC 2017-09-01
Series:	Современная ревматология
Subjects:	ankylosing spondylitis infliximab remicade® biosimilar bcd-055.
Online Access:	https://mrj.ima-press.net/mrj/article/view/770
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

Comparative efficacy and safety of infliximab biosimilar (BCD-055) and innovator infliximab in patients with ankylosing spondylitis (results of international, multiple-center, double-blind phase I and phase III clinical studies)

Similar Items